Author name: antonheyman

Still More Caution Urged Over Osteoporosis Drugs

The newest cautionary note appears in a study published this week in the Archives of Internal Medicine that found the incidence of atypical thigh fractures in women who use these medicines increased over a 12-year period, although the absolute number of such fractures was still very small. http://www.pharmalot.com/2012/05/still-more-caution-urged-over-osteoperosis-drugs/

Still More Caution Urged Over Osteoporosis Drugs Read More »

E-Prescribing Growth Could Bode Well for Med Adherence

The technology improves the rate at which patients actually pick up a new prescription at the pharmacy. Patients picked up their meds 69.5% of the time among physicians who telephoned in, faxed, or hand-wrote new prescriptions, according to a 2011 Surescripts study of some 40 million prescription records between 2008 and 2010. Among physicians who

E-Prescribing Growth Could Bode Well for Med Adherence Read More »

The Automated Pharmacy Dispensing Machine called Rowa

The Rowa is an electronically controlled automated storage system, which offers the capacity of a distinctly larger, conventional storage, while taking up only a minimum of space. The modular construction of this automated storage system allows it to be tailored optimally to every pharmacy’s individual requirements. The sophisticated technology ensures prompt delivery of articles as

The Automated Pharmacy Dispensing Machine called Rowa Read More »

Zithromax (azithromycin): FDA Statement on risk of cardiovascular death

ISSUE: FDA notified healthcare professionals that it is aware of the study published in the New England Journal of Medicine May 17, 2012 reporting a small increase in cardiovascular deaths, and in the risk of death from any cause, in persons treated with a 5-day course of azithromycin (Zithromax) compared to persons treated with amoxicillin,

Zithromax (azithromycin): FDA Statement on risk of cardiovascular death Read More »

FDA Puts 16 Drugs on Watch List

Potential Signals of Serious Risks/New Safety Information Identified by AERS, October to December 2011 – http://www.medscape.com/viewarticle/762205?src=mp&spon=38 . Product Name: Active Ingredient   (Trade) or Product Class Potential Signal of a Serious   Risk/New Safety Information Additional Information (as of   February 15, 2012)* Bortezomib (Velcade, Takeda) Death from intrathecal   administration (medication error) The Dosage

FDA Puts 16 Drugs on Watch List Read More »